Indications
Fempro Tablet is used for:
Breast cancer
Adult Dose
Oral
Advanced or locally advanced breast cancer ; Adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer
Adult: 2.5 mg once daily.
Hepatic impairment: Reduce dose by 50% in patients with cirrhosis and severe hepatic impairment; recommended dose: 2.5 mg on alternate days.
Child Dose
Renal Dose
Administration
May be taken with or without food.
Contra Indications
Premenopausal women and children; hypersensitivity.
Precautions
Severe renal impairment; severe hepatic impairment; osteoporosis. Caution when driving or operating machinery.
Lactation: not known if excreted in breast milk (for post-menopausal women)
Pregnancy-Lactation
Interactions
Plasma levels reduced by tamoxifen.
Adverse Effects
Side effects of Letrozole :
Hot flushes, arthralgia, nausea, vomiting, fatigue, dizziness, headache, dyspepsia, constipation, diarrhoea, anorexia, alopoecia, increased sweating, rash, peripheral oedema, osteoporosis, musculoskeletal pain, vaginal irritation.
Potentially Fatal: Thromboembolic events.
Mechanism of Action
Letrozole competitively binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgen to oestrogen, leading to inhibition of the enzyme and a significant reduction in plasma oestrogen levels.
Note
Fempro 2.5mg Tablet manufactured by Cipla Ltd.. Its generic name is Letrozole. Fempro is availble in Nepal.
Farmaco Nepal drug index information on Fempro Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.